Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont
By Colin Kellaher
Neurocrine Biosciences has won Food and Drug Administration priority review of its proposed treatment for the rare genetic endocrine disorder congenital adrenal hyperplasia, or CAH.
Neurocrine on Monday said the FDA has set target action dates in late December for its decision on a pair of applications seeking approval of crinecerfont in the treatment of children, adolescents and adults with classic CAH.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
The San Diego biopharmaceutical company said an FDA green light would make crinecerfont the first new treatment option for CAH in 70 years.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 01, 2024 08:09 ET (12:09 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst